Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Amgen and AstraZeneca have hopes for their asthma drug Tezspire as a potential COPD treatment. Additionally, Regeneron and Sanofi have a second COPD candidate in IL-33 inhibitor itepekimab ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

have fueled the top line for Sanofi and Regeneron. SNY and REGN are working to expand the drug’s label further. The FDA earlier approved Dupixent for chronic obstructive pulmonary disease (COPD).

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase 3 trials ... billion (+23% YoY), annualizing over $15 billion. Regeneron’s total addressable commercial market ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Based on genetic data linking IL-33 with increased risk of COPD and Phase 2 results, Regeneron’s next innovation in COPD offers potential for benefit in a broader population, including former ...

Regeneron collaborates with Truveta and leading ... The recent approval and launch in chronic obstructive pulmonary disease (COPD) has had a successful start, with coverage secured from the ...